Congenital fibrosarcoma (CFS) and cellular mesoblastic nephroma (CMN) are pediatric spindle cell malignancies that share two specific cytogenetic abnormalities: trisomy of chromosome 11 and a t(12;15)(p13;q25) translocation. The t(12;15) rearrangement creates a transcriptionally active fusion gene that encodes a chimeric oncoprotein, ETV6-NTRK3 (EN). EN transforms NIH3T3 fibroblasts through constitutive activation of both the Rasmitogen-activated protein kinase (MAPK) pathway and the phosphatidylinositol-3'kinase (PI3K)-Akt pathway. However, the role of trisomy 11 in CFS and CMN remains unknown. In this study we demonstrate elevated expression of the chromosome 11p15.5 insulin-like growth factor 2 gene (IGF2) in CFS and CMN tumors. Moreover, we present evidence that an intact IGF signaling axis is essential for in vitro EN-mediated transformation. EN only very weakly transformed socalled R-murine fibroblasts derived from mice with a targeted disruption of the IGF1 receptor gene (IGFRI), but transformation activity was fully restored in R7 cells engineered to re-express IGFRI (R+ cells). We also observed that the major IGFRI substrate, insulinreceptor substrate-1 (IRS-1), was constitutively tyrosine phosphorylated and could be co-immunoprecipitated with EN in either R7 or R+ cells expressing the EN oncoprotein. IRS-1 association with Grb2 and PI3K p85, which link IGFRI to the Ras-MAPK and PI3K-Akt pathways, respectively, was enhanced in both cell types in the presence of EN. However, activation of the Ras-MAPK and PI3K-Akt pathways was markedly attenuated in EN-expressing R7 cells compared to ENtransformed R+ cells. This suggests that IRS-1 may be functioning as an adaptor in EN signal transduction, but that a link to EN transformation pathways requires the presence of IGFRI. Our findings indicate that an intact IGF signaling axis is essential for EN transformation, and are consistent with a role for trisomy 11 in augmenting this pathway in EN expressing tumors.
Introduction
Congenital fibrosarcoma (CFS) and cellular mesoblastic nephroma (CMN) are spindle cell malignancies of infancy and young childhood that are closely related both clinically and histopathologically (Fisher, 1996; O'Malley et al., 1996) . These tumors are genetically related as well, sharing common genetic abnormalities including expression of the t(12;15)(p13;q25)-associated ETV6-NTRK3 gene fusion (Knezevich et al., 1998b) and trisomy of chromosome 11 (Knezevich et al., 1998a; Rubin et al., 1998) . The ETV6-NTRK3 fusion product (EN) contains the sterile-alpha domain (SAM; also called the pointed or helix -loop -helix domain) of the ETS transcription factor, ETV6, fused to the cytoplasmic portion containing the protein tyrosine kinase domain (PTK) of the neurotrophin-3 receptor, NTRK3. The SAM domain enables EN to undergo homodimerization and ligand-independent activation of the PTK domain, which is required for its potent transformation activity in NIH3T3 cells (Wai et al., 2000) . We have recently shown that the transforming properties of EN are associated with constitutive activation of NTRK3 signaling pathways, namely the Ras-MAPK and phosphatidylinositol-3'kinase (PI3K)-Akt cascades (Tognon et al., 2001) . However, the adaptor proteins that link EN to activation of these pathways have yet to be identified, as we failed to show a direct association between EN and known NTRK3-associating molecules including Shc, Grb2, PI3K p85, ABL, SH2Bb, Src, or Ship2 (Tognon et al., 2001; Wai et al., 2000) .
Trisomy 11 has been reported in the majority of cases of CFS and CMN (Bernstein et al., 1994; Dal Cin et al., 1998; Kaneko et al., 1991; Knezevich et al., 1998a,b; Mascarello et al., 1994; Rubin et al., 1998; Schofield et al., 1993 Schofield et al., , 1994 ). As well, high level expression of the peptide hormone insulin-like growth factor 2 (IGF2) have been reported in CMN tissue (Sharifah et al., 1995) . Given that the IGF2 gene is localized to the 11p15.5 region of chromosome 11, we speculated that the extra copy of chromosome 11 might lead to over-expression of IGF2 in CFS and CMN, and therefore that activation of the IGF pathway is important for EN-mediated tumorigenesis.
IGF1 and IGF2 both bind to IGFRI and stimulate multiple signaling cascades, including mitotic, antiapoptotic, and transformation-associated pathways (reviewed in Baserga, 2000) . Ligand binding results in receptor PTK autophosphorylation and activation, followed by tyrosine phosphorylation of key substrates including insulin receptor substrate-1 (IRS-1), Shc, and PI3 kinase (PI3K) p85 subunit (reviewed in . Two major downstream signaling pathways are associated with IGFRI activation: IRS-1 and Shc binding lead to activation of the Ras-Raf1-MEK-ERK1/2 MAP kinase mitogenic cascade (Downward, 1996; Joneson and Bar-Sagi, 1997) , and binding of the PI3K p85 subunit leads to activation of the PI3K-AKT cell survival pathway (Dudek et al., 1997; Franke et al., 1997a,b) . A large amount of literature points to a critical role for this signaling system in cellular transformation. IGFRI activation or ligand overexpression has been described in a number of adult malignancies including breast and prostate cancer as well as in pediatric malignancies such as rhabdomyosarcoma, Wilms' tumor, neuroblastoma, Ewing family tumors, and acute leukemias (reviewed in Baserga, 1995 Baserga, , 1999 Toretsky and Helman, 1996; Werner, 1998) . The functional significance of the IGF signaling axis in oncogenesis has been demonstrated experimentally by the anti-tumorigenic effects of IGFRI antisense oligonucleotides (Neuenschwander et al., 1995; Pass et al., 1996; Resnicoff et al., 1994a,b) and dominant negative IGFRI constructs (Burgaud et al., 1995; D'Ambrosio et al., 1996; Dunn et al., 1998; Prager et al., 1994; Reiss et al., 1998) . Moreover, a number of dominantly-acting oncogenes such as simian virus 40 T antigen (Sell et al., 1993) , Ha-Ras , and c-Src (Valentinis et al., 1997) , viruses such as bovine and human papilloma virus (Steller et al., 1996) , and overexpressed growth factor receptors such as PDGFR and EGFR , fail to transform mouse embryo fibroblasts generated from IGFRI knockout mice (known as R7 cells). Among oncoproteins involved in childhood solid tumors, this requirement for intact IGFRI signaling includes the EWS-FLI1 and PAX3-FKHR fusion proteins of Ewing family tumors and alveolar rhabdomyosarcoma, respectively (Toretsky et al., 1997; Wang et al., 1998) .
In this study we asked whether an intact IGFRI signaling axis is required for the transformation activity of the EN chimeric oncoprotein. We first screened CFS and CMN primary tumors and found high levels of IGF2 expression in all cases analysed. To test whether the IGF pathway is important for ENmediated transformation, we compared the transforming activity of EN in IGFRI null R7 cells to that observed in R+ cells, which are R7 cells engineered to re-express IGFRI using retroviral gene transfer. We found that while the fusion protein was very weakly transforming in R7 cells, transformation activity was fully restored when EN was expressed in R+ cells. Expression of the fusion protein correlated with constitutive tyrosine phosphorylation of IRS-1 in both cell types, and IRS-1 was able to bind and pull down Grb2 and the p85 regulatory subunit of PI3K equally well in each cell line. Moreover, co-immunoprecipitation experiments suggested that EN and IRS-1 were present in complexes in both R7 and R+ cells. However, while activation of pathways essential for EN transformation, the Ras-MAPK and PI3K-Akt cascades, was markedly attenuated in EN-expressing R7 cells, these pathways were enhanced in ENexpressing R+ cells. Although these data are consistent with IRS-1 serving as an adaptor protein for EN, they indicate that it requires the presence of IGFRI in order to efficiently activate downstream pathways essential for EN transformation.
Results

IGF2 is overexpressed in CFS and CMN primary tumors
Given the strong association between the expression of the ETV6-NTRK3 gene fusion and the presence of trisomy 11 in CFS and CMN (Knezevich et al., 1998a; Rubin et al., 1998) , we postulated that the extra copy of chromosome 11 might lead to increased expression of a gene critical for EN transformation. Since IGF2 over-expression in CMN has already been described (Sharifah et al., 1995) , we assessed mRNA levels of this gene in EN-expressing tumors. Northern blotting was used to analyse IGF2 transcripts in primary tumor sample specimens of fusion positive CFS and CMN with trisomy 11. We also tested cases of infantile fibromatosis and the classical form of mesoblastic nephroma, which are benign counterparts of CFS and CMN, respectively, that lack this gene fusion as well as trisomy 11 (Bourgeois et al., 2000; Knezevich et al., 1998a) . A typical result is shown in Figure 1 , demonstrating high IGF2 expression in CFS and CMN, but low to negligible levels in infantile fibromatosis and classical mesoblastic nephroma. This was confirmed by quantitative RT -PCR of five cases of fusion positive CFS and CMN with trisomy 11, which demonstrated 10 -30-fold higher levels of IGF2 expression as compared to normal fibroblast cultures (data not shown). These findings indicate that overexpression of the IGF2 gene is associated with trisomy 11 in CFS and CMN.
Expression of EN in R7 and R+ murine fibroblasts
Given the high IGF2 mRNA levels in EN-expressing tumors, we hypothesized that the IGF signaling axis may serve an important function in EN-mediated transformation. NIH3T3 cells are known to express moderately high levels of IGFRI protein which can be difficult to block experimentally (Baserga, 1999) . Therefore to directly test whether IGFRI signaling is required for EN transformation, we chose to assess the in vitro transforming properties of EN in R7 cells, which are murine 3T3 fibroblast cells derived from IGFRI knockout mice Liu et al., 1993) . We used retroviral gene transfer to generate R7 cell lines containing vector alone or stably expressing EN or an activated form of Ha-Ras (R7, R7EN and R7Ha-Ras, respectively). As controls, we stably reexpressed IGFRI in R7 cells, creating so-called R+ cells positive for IGFRI. Expression of IGFRI in these cells was confirmed by immunoprecipitation with the a-IR3 IGFRI monoclonal antibody followed by Western blotting with an a-IGFRI b-subunit antibody, demonstrating the 97 kDa IGFRI b-subunit (see Figure 2a) . Retroviral gene transfer was similarly used to generate R+ cell lines containing vector alone or stably expressing EN or activated Ha-Ras (R+, R+EN and R+Ha-Ras, respectively). Immunoblotting demonstrated equivalent expression of the characteristic 68 and 73 kDa doublet of EN (Wai et al., 2000) in R7EN and R+EN cells, and confirmed that levels were similar to those in EN-transformed NIH3T3 cells (see Figure 2B ).
EN fails to transform R7 cells
To assess whether IGFRI signaling is required for EN-mediated oncogenesis, we compared the ability of EN to transform R7 versus R+ cells using morphologic criteria and anchorage-independent soft agar colony growth as parameters of transformation (Ponten, 1971) . Vector alone and activated Ha-Ras constructs were used as controls. R7 and R+ cells showed identical non-transformed phenotypes (shown for R7 cells in Figure 3 ), while R7EN ( Figure 3 ) and R7Ras cells demonstrated slight increases in spindle morphology and nuclear-to-cytoplasmic ratios. This suggests that EN and Ha-Ras are only weakly transforming in R7 cells. In contrast, both R+EN ( Figure 3 ) and R+Ras cells were morphologically transformed with spindling, elaboration of cellular processes, increased nuclear-to-cytoplasmic ratios and refractility, and focus formation with loss of contact inhibition. Of note, cell viability was similar in each cell line (data not shown). To confirm these results, cells were plated in soft agar to determine their Figure 1 IGF2 transcripts are over-expressed in CFS and cellular mesoblastic nephroma. Total RNA was extracted from primary tumor samples and subjected to Northern blot analysis using an IGF2 exon 9-specific probe. Arrows show the 6.0 and 4.8 kb IGF2 transcripts in congenital fibrosarcoma (CFS) and the cellular form of mesoblastic nephroma (MN). This is not observed in the classical form of MN nor in infantile fibromatosis (IFB), which are benign lesions lacking the ETV6-NTRK3 gene fusion or trisomy 11. b-actin loading controls are shown in the lower panel Figure 2 Generation of ETV6-NTRK3 (EN) and IGFRI expressing R+ cells. (a) Retroviral gene transfer was used to re-express IGFRI in R7 fibroblasts derived from mice with a targeted disruption of the IGFRI gene, creating so-called R+ cells. Expression of IGFRI in R+ cells was compared to parental R7 cells and IGFRI-expressing P6 control cells by immunoprecipitation from whole cell lysates using a-IR3 monoclonal antibodies, followed by Western blotting with antibodies to the IGFRI b-subunit (arrow). (b) Retroviral gene transfer was used to express ETV6-NTRK3 (EN), Ha-Ras (Ras), and vector alone (Vec) constructs in R7 and R+ cells. To confirm that levels of EN protein expression were similar in these cells and in EN transformed NIH3T3 cells, whole cell lysates were subjected to immunoprecipitation with a-ETV6 antibodies followed by Western blotting with a-NTRK3 antibodies. Arrows demonstrate the 68/73 kDa doublet of EN ability to grow under anchorage independent conditions. While R7EN cells formed occasional macroscopic soft agar colonies, this property was significantly enhanced for R+EN cells (P=0.0001; see Figure 4a ). As well, the size of the colonies formed by R+EN were greater in diameter as compared to R7EN (see Figure 4a ). In fact, EN and Ha-Ras both failed to induce significant colony formation in R7 cells but this property was rescued by expression in R+ cells (see Figure 4b ). Even though R+ cells alone formed small but reproducible colony numbers, rates were significantly higher for R+ cells expressing EN (P50.01 for R+ versus R+EN) or Ha-Ras. These studies indicate that IGFRI is required for full EN-mediated transformation.
Mek1/2 and Akt activation are attenuated in ENexpressing R7 cells
We recently demonstrated that EN transformation is dependent on constitutive activation of the Ras-MAPK and PI3K-Akt pathways (Tognon et al., 2001) . We therefore hypothesized that the failure of EN to fully transform cells lacking IGFRI might be due to defects in the activation of these pathways. To assess this possibility, we examined the activation states of Mek1/2 and Akt molecules in R7EN and R+EN cells. Under low serum conditions R7EN and R+EN cells demonstrated equivalent levels of basal activation of Mek1/2 and Akt (see Figure 5 ). Both were greater than those observed in R7 cells alone, consistent with previous findings in ENexpressing NIH3T3 cells (Tognon et al., 2001) . However, while serum stimulation led to a marked increase in activation of Mek1/2 and Akt in R+EN cells, this was not observed in R7EN cells where levels of phosphorylated Mek1/2 and Akt remained at basal levels even after serum stimulation ( Figure  5 ). This was peculiar to R7EN cells, as R7 cells alone (see Figure 5 ) as well as R+ cells (data not shown), responded to serum stimulation as expected by maximally activating Mek1/2 and Akt. Therefore cellular mechanisms for activating Ras-MAPK and PI3K-Akt pathways (e.g. through other growth factor receptors) are intact in R7 cells. These observations were consistent over many independent experiments, and persisted even after longer term serum stimulation (data not shown). Therefore 
EN expression leads to constitutive IRS-1 tyrosine phosphorylation in NIH3T3 fibroblasts
Adapter proteins linking EN to activation of Ras-MAPK and PI3K-Akt pathways remain to be determined (Wai et al., 2000) . Recent studies suggest that the major IGFRI substrate, insulin-receptor substrate-1 (IRS-1), may serve as a molecular bridge between the NTRK1 receptor and activation of the Ras-MAPK and PI3K-Akt pathways (Miranda et al., 2001) . Moreover, Yamada and co-workers have reported that NTRK2 activation is associated with increased IRS-1 tyrosine phosphorylation and recruitment of the p85 regulatory subunit of PI3K (Yamada et al., 1997) . We therefore hypothesized that IRS-1 might be acting as an adapter linking EN to downstream signaling pathways. To assess this possibility, we first analysed the tyrosine phosphorylation status of IRS-1 in the presence and absence of EN. NIH3T3 cell lines grown under serum-free conditions showed a tyrosine phosphorylated band at 185 kDa by Western blotting in EN-expressing cells but not in vector controls (see top panel, Figure 6a ). This band became tyrosine phosphorylated in vector controls only after serum or IGF2 stimulation (top panel, Figure 6a ). Reprobing of the blot with an IRS-1 specific antibody revealed that the 185 kDa differentially phosphorylated band corresponds to IRS-1 (bottom panel, Figure 6a ). This was confirmed by immunoprecipitation of lysates from serum-starved NIH3T3 cells using an IRS-1 specific antibody, which revealed markedly increased levels of tyrosine phosphorylation of IRS-1 in ENexpressing cells compared with vector controls (see Figure 6b ). Therefore IRS-1 undergoes constitutive tyrosine phosphorylation in NIH3T3 fibroblasts expressing EN.
Constitutive IRS-1 tyrosine phosphorylation is maintained in EN-expressing R7 cells
We next tested whether the constitutive tyrosine phosphorylation of IRS-1 observed in EN-expressing cells is dependent on the presence of IGFRI. R7EN and R+EN cells along with R7 and R+ vector controls were subjected to Western blotting using aphosphotyrosine antibodies, which demonstrated equivalent levels of a 185 kDa tyrosine phosphorylated band in the EN-expressing cells even in the absence of serum or IGF2 (see Figure 7a ). This band was present only at basal levels in serum-or IGF2-deprived R7 and R+ cells. Its tyrosine phosphorylation was induced by serum or IGF2 stimulation in R+ cells but not in R7 cells (as expected given that they do not express IGFRI). Blots were re-probed with an a-IRS-1 antibody to verify the identity of the 185 kDa band as IRS-1 (data not shown). As shown in Figure 7b , these findings were confirmed by immunoprecipitation studies using an IRS-1 specific antibody. While R7 cells demonstrated only very low basal levels of tyrosine phosphorylated IRS-1, R+EN and R7EN (7) ETV6-NTRK3 constructs were grown in 35 mm dishes to 75% confluence and then serum-deprived in 0.5% serum DMEM for 18 h. Cells were then stimulated with or without 9% serum for the indicated times. Whole cell lysates were collected and used for Western blot analysis with antibodies to activated Akt (phospho-Akt) or activated Mek1/2 (phosphoMek). Western blotting using Grb2 antibodies was used to demonstrate equal protein loading (7) ETV6-NTRK3 retroviral constructs were grown in 35 mm dishes to 75% confluence and then serum-deprived for 18 h in 0.5% serum. Cells were then stimulated with or without 9% serum or 50 ng/ml of IGF2 for 30 min. Whole cell lysates were prepared and separated by SDS -PAGE and probed with PY20 anti-phosphotyrosine antibodies (P-Tyr). The top panel shows a differentially tyrosine phosphorylated band at approximately 185 kDa, which was confirmed to be IRS-1 by re-probing with a-IRS-1 antibodies (IRS-1). (b) Immunoprecipitation analysis. NIH3T3 infected with (+) or without (7) ETV6-NTRK3 retroviral constructs were grown in 9% calf serum to 75% confluence. Whole cell lysates were then prepared (1000 mg total protein) and subjected to immunoprecipitation using a-IRS-1 antibodies. Immunoprecipitates were separated by SDS -PAGE and probed with PY20 anti-phosphotyrosine antibodies (top panel), followed by re-probing with a-IRS-1 antibodies (bottom panel). Arrows show the position of the 185 kDa IRS-1 band cells showed equivalently elevated levels of IRS-1 tyrosine phosphorylation even in the absence of serum. These findings indicate that there is constitutive tyrosine phosphorylation of IRS-1 in EN-expressing cells, and that this does not depend on the presence of IGFRI.
IRS-1 co-immunoprecipitates with EN
It is possible that IRS-1 functions in EN signaling as part of a molecular complex with EN. To begin to test this hypothesis we carried out co-immunoprecipitation experiments to investigate potential interactions between these two molecules. R+EN cells were lysed after serum stimulation and subjected to immunoprecipitation using either an a-HLH-ETV6 antibody or a control IgG antibody. As shown in lane 1 of Figure 8a , a-ETV6 antibodies were able to co-immunoprecipitate a 68/73 kDa doublet (confirmed to be EN by reprobing with a-NTRK3 antibodies; not shown) along with a tyrosine-phosphorylated band at 185 kDa, neither of which were observed using non-specific IgG (Figure 8a, lane 2) . The latter band was identical in size to a 185 kDa tyrosine-phosphorylated protein immunoprecipitated from serum-stimulated parental R+ cells (which contain high IRS-1 levels) using a-IRS-1 antibodies (Figure 8a, lane 3) . This band was not observed when a-ETV6 antibodies were used for immunoprecipitation in R+ (or R7 cells) lacking EN expression (data not shown). To show that this 185 kDa protein represented IRS-1, the blot was reprobed with the a-IRS-1 antibody (see lanes 1 and 3 of Figure 8b ). Identical results were found using R7EN cells, in which we also observed co-immunoprecipitation of EN and the 185 kDa tyrosine phosphorylated band (data not shown). This indicates that IGFRI is not required for the EN/IRS-1 interaction.
To independently confirm these findings using a different cell line, we performed the reverse experiment in EN-transformed NIH3T3 cells using either a-ETV6 or a-IRS-1 antibodies for the immunoprecipitation step. This showed that the characteristic EN doublet could be pulled down with both antibodies (see Figure  9a ). The identity of this doublet was confirmed to be EN by Western blotting using a-NTRK3 antibodies, and its tyrosine phosphorylation was verified by prior blotting with a-phosphotyrosine antibodies (data not shown). Co-immunoprecipitation of EN and IRS-1 was not affected by mutating tyrosine 594 of EN to phenylalanine (see Figure 9a ). This amino acid corresponds to tyrosine 464 of NTRK1, mutation of , and R+EN cells (IGFRI+; ETV6-NTRK3+) were grown in 35 mm dishes to 75% confluence and then serum-deprived for 18 h in 0.5% serum. Cells were then stimulated with or without 9% FBS/DMEM or 50 -100 ng/ml IGF2 as indicated for 3 h. Whole cell lysates were prepared for Western blotting using PY20 anti-phosphotyrosine antibodies (P-Tyr) (top panel), which demonstrated differential tyrosine phosphorylation of a 185 kDa band (arrow). This band was confirmed to be IRS-1 by stripping and re-probing with a-IRS-1 antibodies (data not shown). Grb2 blotting was used to control for equal protein loading of samples. (b) Immunoprecipitation analysis: R7, R7EN and R+EN cells were serum-deprived as in (b) and then stimulated with or without 9% FBS/ DMEM for 30 min. Equal protein amounts (1000 mg) from whole cell lysates were subjected to immunoprecipitation using a-IRS-1 antibodies, followed by Western blotting with PY20 anti-phosphotyrosine antibodies (P-Tyr) (top panels). This revealed immunoprecipitation of a 185 kDa tyrosine phosphorylated band, which was confirmed to be IRS-1 by re-probing with a-IRS-1 antibodies (bottom panels) Figure 8 ETV6-NTRK3 co-immunoprecipitates with IRS-1. (a) Immunoprecipitation was carried out from R+EN whole cell lysates (lanes 1 and 2) using a-ETV6 antibodies (lane 1) or normal rabbit IgG (lane 2), or from control R+ lysates (lane 3) using a-IRS-1 antibodies, followed by Western blotting with PY20 antiphosphotyrosine antibodies (P-Tyr). The arrow shows the position of a 185 kDa tyrosine phosphorylated protein in lanes 1 and 3. P68/p73 refers to the immunoprecipitated EN doublet. (b) Reprobing of the blot with a-IRS-1 antibodies shows that the p185 band represents IRS-1 which was previously shown to abolish the interaction between IRS-1 with NTRK1 (Miranda et al., 2001) . We did observe, however, that the EN/IRS-1 association requires a functional EN PTK domain. The nontransforming EN-K380N kinase dead mutant (Wai et al., 2000) could not be pulled down using a-IRS-1 antibodies even though it was expressed at similar levels as EN (Figure 9a) . Moreover, IRS-1 tyrosine phosphorylation was markedly diminished in NIH3T3 cells expressing this mutant compared with EN (see Figure 9b ). In view of the findings of Miranda et al. (2001) on the interaction between IRS-1 and NTRK1, we also tested whether mutations of any of the three most C-terminal tyrosines of EN affected IRS-1 tyrosine phosphorylation. However, none of these mutants showed diminished IRS-1 tyrosine phosphorylation (Figure 9b ), consistent with each mutant retaining full transformation activity (data not shown). These studies provide preliminary evidence that IRS-1 is involved in complex formation with EN, although it is not yet known whether this is a direct or indirect interaction. We also attempted to pull down EN using a-IGFRI b-subunit antibodies (or IGFRI with a-NTRK3 antibodies) but have been unable to reproducibly show an association between EN and IGFRI (data not shown). Therefore it remains unclear whether IGFRI is also part of this complex. It also remains to be determined whether EN is directly responsible for the constitutive tyrosine phosphorylation of IRS-1 observed in EN-expressing cells.
Recruitment of Grb2 and p85 by IRS-1 is maintained in EN-expressing R7 cells
The constitutive tyrosine phosphorylation of IRS-1 in R7EN cells suggested that the attenuated levels of Mek1/2 and Akt activation in response to serumstimulation observed in these cells (see Figure 5) was not due to a defect in IRS-1 tyrosine phosphorylation secondary to the absence of IGFRI. IRS-1 is an important adapter protein for the IGF and insulin signaling cascades (Myers and White, 1996) . In response to IGF or insulin stimulation IRS-1 becomes tyrosine phosphorylated and recruits SH2-containing proteins such as Grb2, SHP-2, and the PI3K p85 regulatory subunit, in turn activating downstream Ras-MAPK, PI3K-Akt and other pathways (Myers and White, 1996) . It is therefore possible that IRS-1 is not able to recruit downstream signaling molecules in the absence of the IGFRI protein. To test if this might be the basis for the observed lack of maximal Ras-MAPK and PI3K-Akt activation in R7EN cells and potentially why these cells are not transformed, we wished to assess whether there were differences in IRS-1 recruitment of Grb2 and p85 in R7EN versus R+EN cells. We therefore performed immunoprecipitation from lysates of EN-expressing R7 and R+ cells before and after serum stimulation using antibodies to IRS-1. As before, the levels of tyrosine phosphorylated IRS-1 were very low in R7 (see Figure 10 ) and R+ cells (not shown), but were markedly increased in R7EN and R+EN cells even in the absence of serum (see Figure  10) . However, the EN-induced increase in IRS-1 tyrosine phosphorylation correlated with enhanced recruitment of Grb2 and p85 in both R7EN and R+EN cells. There was no significant difference in the levels of Grb2 and p85 recruited by IRS-1 in R7EN versus R+EN cells. Therefore the presence of IGFRI does not appear to influence the ability of IRS-1 to recruit these signaling adapters to the putative EN/ IRS-1 complex, and other mechanisms must underlie the complementary role of IGFRI in EN-mediated transformation.
Discussion
In this study we evaluated the role of the IGFRI signaling axis in transformation of fibroblasts by the CFS and CMN-associated ETV6-NTRK3 chimeric oncoprotein. We have previously shown that EN transformation involves links between known NTRK3 signaling pathways and aberrant cell cycle progression, Figure 9 Co-immunoprecipitation of IRS-1 and ETV6-NTRK3 using a-IRS-1 antibodies. (a) NIH3T3 cells expressing vector alone (Vec), ETV6-NTRK3 (EN), the kinase dead EN-K380N non-transforming mutant (KD), or the EN-Y594F transforming mutant (Y594F) were grown to near confluence in 9% FBS/ DMEM. Whole cell lysates (1000 mg) were collected and subjected to immunoprecipitation with a-ETV6 as well as with a-IRS-1 antibodies. Immunoprecipitates were separated by SDS -PAGE and subjected to PY20 anti-phosphotyrosine immunoblotting. A tyrosine phosphorylated doublet at 68 and 73 kDa is seen in lysates from EN and EN-Y594F expressing cells, which is confirmed to represent EN by re-probing with a-NTRK3 antibodies (data not shown). (b) NIH3T3 cells expressing ETV6-NTRK3 (EN), EN-K380N (KD), or the three C-terminal tyrosine mutants EN-Y620F, EN-Y594F, or EN-Y560F (all of which retain transformation activity) were cultured in 9% FBS/DMEM to near confluence. Whole cell lysates were then prepared and a 1000 mg protein aliquot was immunoprecipitated using a-IRS-1 antibodies, followed by Western blotting with PY20 anti-phosphotyrosine antibodies. This revealed immunoprecipitation of a 185 kDa band (arrow in top panel) which re-probed with a-IRS-1 antibodies (arrow in bottom panel) and that the Ras-MAPK and PI3K-Akt pathways act synergistically to mediate these effects (Tognon et al., 2001; Wai et al., 2000) . A possible role for IGF signaling in this process was first suggested to us by the striking correlation found between the presence of the ETV6-NTRK3 gene fusion and trisomy 11 (Knezevich et al., 1998a; Rubin et al., 1998) . We hypothesized that trisomy 11, well known to occur in both CFS and CMN (Bernstein et al., 1994; Dal Cin et al., 1998; Kaneko et al., 1991; Mascarello et al., 1994; Schofield et al., 1993 Schofield et al., , 1994 , leads to over-expression of a chromosome 11 gene or genes important for EN oncogenesis. A prime candidate was the 11p15.5 IGF2 gene whose expression is elevated in numerous pediatric malignancies (reviewed in Toretsky and Helman, 1996) , including CMN (Sharifah et al., 1995) . Consistent with our hypothesis, we confirmed that IGF2 transcripts are markedly increased in ENexpressing primary CFS and CMN cases with trisomy 11. IGF2 is an imprinted gene that is normally expressed only from the paternal allele (reviewed in Polychronakos et al. (1995) ). Analysis of two of the CFS and CMN primary tumors from the current study revealed that the extra copy of chromosome 11 was paternally derived (data not shown), thus providing a possible mechanism for the observed over-expression of IGF2 in such lesions. These observations prompted us to characterize the pathophysiologic role of the IGF/ IGFRI axis in cells transformed by ETV6-NTRK3. EN was incapable of fully transforming R7 mouse fibroblasts lacking IGFRI expression; this was also observed with Ha-Ras, as has been previously reported . Interestingly, R7EN and R7Ras cells did show increased saturation densities compared with R7 cells alone (Figure 3 ), suggesting that they were partially transformed as observed for R7 cell expressing SV40 large T antigen (Sell et al., 1993) . Full transformation activity was restored for both oncoproteins by re-expression of IGFRI in these cells. When we assessed Ras-MAPK and PI3K-Akt activation in R7EN cells, we found that both were markedly attenuated compared with R+EN cells, consistent with the lack of transformation of the former by EN. These findings indicate that EN, like several other dominantly-acting oncoproteins, requires a functional IGF/IGFRI axis for transformation. In fact, IGFRI signaling axis has been found to be essential for transformation mediated by other pediatric tumor fusion genes, including EWS/FLI1 of Ewing tumors (Toretsky et al., 1997) and PAX3-FKHR of alveolar rhabdomyosarcoma (Wang et al., 1998) . This, coupled with widespread over-expression of IGFs in pediatric neoplasms, suggests that the IGF/IGFRI axis plays a generalized role in childhood cancer (Toretsky and Helman, 1996) .
Since transformation is blocked in R7 cells expressing EN and these cells show attenuation of Ras-MAPK and PI3-Akt pathways essential for EN transformation, we hypothesized that IGFRI may somehow link EN to these pathways. Previous studies in our laboratory confirmed that because of the position of the t(12;15) breakpoints, the wild-type NTRK3 binding sites for SHC, GRB2, p85 and other known adaptors are not present in EN and the chimeric oncoprotein does not bind these molecules (Knezevich et al., 1998b; Tognon et al., 2001; Wai et al., 2000) . Therefore adaptor proteins for EN remain unknown. Insulin receptor substrate-1 (IRS-1) serves an important adaptor function for IGF and insulin signaling cascades (Myers and White, 1996) . IRS-1 becomes tyrosine phosphorylated with IGF stimulation and recruits SH2-containing proteins such as Grb2/ mSos, SHP-2, and p85 to IGFRI (Giovannone et al., 2000) . These events in turn activate downstream pathways including Ras-MAPK and PI3K-Akt. Both IRS-1 and the related protein IRS-2 have been reported to act as direct substrates for other NTRK family members, namely NTRK1 (Miranda et al., 2001 ) and NTRK2 (Yamada et al., 1997) . This led us to assess whether IRS-1 functions as an adaptor molecule in EN transformed cells. We found that EN expression leads to constitutive IRS-1 tyrosine phosphorylation in NIH3T3 cells, and that IRS-1 can be pulled down with antibodies to EN or vice versa in these cells. This suggests that EN and IRS-1 associate with each other in EN-expressing cells. It is not yet known whether EN directly phosphorylates IRS-1, although we did find that both IRS-1 tyrosine phosphorylation and its association with EN were blocked if the kinase domain of EN was inactivated by site-directed mutagenesis. Although our data implicate IRS-1 as an EN interactor and possibly as a link between EN and oncogenic signaling pathways, Figure 10 Recruitment of Grb2 and PI3K p85 subunit by IRS-1 is retained in both R+EN and R7EN cells. R7, R7EN and R+EN cells were cultured to 75% confluency in 100 mm dishes and then placed in 0.5% serum for 18 h. Cells were then stimulated with 9% FBS/DMEM for the indicated times and whole cell lysates were prepared using standard methods. Equivalent amounts of protein (1000 mg) were subjected to immunoprecipitation using a-IRS-1 antibodies, followed by Western blotting with the indicated antibodies. The top two rows represent a 185 kDa protein immunoblotted with anti-phosphotyrosine antibodies (PTyr) or a-IRS-1 antibodies (IRS-1). The bottom two rows show immunoblotting results using antibodies against the PI3K p85 subunit (p85) or Grb2 (Grb2), respectively tyrosine phosphorylation of IRS-1 and its association with EN could also be detected in non-transformed R7EN cells. Moreover, we found that tyrosine phosphorylated IRS-1 associated with Grb2 and p85 equally well in R+EN and R7EN cells (Figure 10 ), even though activation of Ras-MAPK and PI3K-Akt is attenuated in R7EN cells ( Figure 5) . Therefore it appears that tyrosine phosphorylation of IRS-1 and association with EN are not sufficient for EN transformation, and that IGFRI is still required for this process and for maximal activation of oncogenic pathways.
There are several possible explanations for the above findings. First, it is possible that EN mediated tyrosine phosphorylation of IRS-1 occurs at different tyrosine residues in the presence and absence of IGFRI. Even though tyrosine phosphorylated IRS-1 can associate with Grb2 and p85 in R7EN cells, this interaction may be limited in its ability to activate Ras-MAPK and PI3K-Akt, respectively, due to conformational or other issues related to the specific IRS-1 residues that are phosphorylated in R7EN cells. We are currently mapping the phosphorylation sites in IRS-1 to test this hypothesis. Second, in the absence of IGFRI one or more phosphatases may be recruited to putative EN/IRS-1 complexes which might compromise Mek and Akt activation. It should be noted that the inability of serum (or IGFs) to maximally activate Mek and Akt in R7EN versus R+EN cells was found over a wide range of incubation times (data not shown), suggesting that the absence of IGFRI may lead to a defect in the ability to activate Ras-MAPK and PI3K-Akt in a sustained manner. Third, IGFRI might be necessary to localize the EN/IRS-1 signaling complexes in such a way as to be able to maximally activate pathways required for transformation. There is increasing evidence that the subcellular localization of IRS-1 is important for its ability to effectively activate downstream pathways (Kriauciunas et al., 2000) . IRS proteins exist in a dynamic equilibrium between the cytoplasm and inner cell membrane compartments (Myers and White, 1996) . The N-terminal pleckstrin homology (PH) domain of IRS-1 is not only essential for efficient tyrosine phosphorylation of IRS-1 upon IGF stimulation (Yenush et al., 1998) , but also appears to be necessary for the translocation of IRS-1 from the cytoplasm to the inner cell membrane during insulin and IGF stimulation (Razzini et al., 2000) . Recent studies with a myristoylated form of IRS-1 in insulin-expressing cells demonstrated that constitutive membrane localization of IRS-1 correlated with decreased p85 binding but with increased Ras-MAPK and PI3K-Akt activation in response to insulin (Kriauciunas et al., 2000) . It is therefore possible that IGFRI, like the insulin receptor, may play a role in localizing IRS-1 (and associated Grb2 and p85) to the inner cell membrane in EN-expressing cells where it can efficiently activate components of the Ras-MAPK and PI3K-Akt pathways required for EN transformation. We are currently analysing whether there is differential localization of IRS-1 in R7EN compared with R+EN cells.
A fourth possible explanation for the discrepancy between IRS-1 tyrosine phosphorylation in R7EN cells and the block in transformation of these cells is that IGFRI is activating one or more IRS-1-independent pathways essential for EN transformation. It was previously found that IGFRI mutants with C-terminal deletions starting at residue 1229 retain mitogenic and survival functions but lose their transformation activity (Hongo et al., 1996; O'Connor et al., 1997; . This suggests that the IGFRI C-terminus may activate an unknown transformation-associated pathway (Baserga, 1999) . R7 cells expressing the Cterminal mutant showed no defects in IRS-1 tyrosine phosphorylation (Valentinis et al., 1997) , indicating that this pathway may be IRS-1-independent. While over-expression of IRS-1 alone is capable of transforming NIH3T3 fibroblasts expressing physiologic levels of IGFRI, over-expression in R7 cells does not result in transformation Fei et al., 1995) . Several recent studies have shed further light on these observations. Using differential display, a notch family protein, DBI-1, was found to be specifically down-regulated in R7 cells re-expressing full length IGFRI compared to those expressing the C-terminal 108 mutant (Hoff et al., 1998) . DBI-1 was subsequently found to be deleted in lung cancer under the name DICE-1, and may represent a tumor suppressor gene down-regulated by IGFRI signaling in transformed cells (Wieland et al., 1999) . The importance of such a pathway in EN transformation remains to be determined. However, unless it is somehow linked to activation of the Ras-MAPK and PI3K-Akt cascades, its absence in R7 cells does not explain our observation that pathways essential for EN transformation are attenuated in R7EN cells and enhanced in R+EN cells.
In summary, our findings indicate that like many other dominantly-acting oncoproteins, EN transformation requires a functional IGFRI signaling axis. While many chromosome 11 genes may be affected by trisomy 11, our results are consistent with a model in which this abnormality contributes to increased IGF2 stimulation of IGFRI. IGFRI stimulation appears to be necessary for full activation of pathways essential for EN transformation, namely the Ras-MAPK and PI3K-Akt cascades. EN can associate with IRS-1 and IRS-1 is constitutively tyrosine phosphorylated in ENexpressing cells. Therefore IRS-1 may be the adaptor that links EN to key mitogenic and survival pathways necessary for its transformation activity. It remains unclear whether the EN/IRS-1 interaction is direct or indirect. Attempts to pull down EN using a-IGFRI antibodies (or the reverse) have so far been unsuccessful in demonstrating an association between EN and IGFRI or whether IGFRI is part of the putative EN/ IRS-1 complex. However, this may be a weak interaction that is not maintained under the conditions we utilized for immunoprecipitation. What is clear from our studies is that EN-mediated IRS-1 tyrosine phosphorylation is insufficient for EN transformation in the absence of IGFRI. This contrasts with a previous report that not only demonstrated an interaction between IRS-1 and the SV40 T-antigen in R7 cells, but that co-transfection of T-antigen and IRS-1 was sufficient to transform these cells (Fei et al., 1995) . Additional studies are necessary to determine if the role of IGFRI in EN transformation is to enhance EN/IRS-1 mediated signaling (such as by juxtapositioning active signaling complexes next to downstream effector cascades), or whether IGFRI is activating novel transformation-associated pathways. Our findings also provide further evidence for overlap between NTRK and IGFRI signaling. An increasing number of reports highlight potential roles for NTRK receptors in oncogenesis (Bongarzone et al., 1989; Miknyoczki et al., 1999; Pahlman and Hoehner, 1996; Reinach and MacLeod, 1986; Reuther et al., 2000; Weeraratna et al., 2000) . Therefore elucidation of pathways activated during EN transformation, such as those involving the IGFRI axis, may provide novel insights into how NTRK signaling contributes to oncogenesis.
Materials and methods
Tissue culture
IGFRI knockout mouse embryo fibroblasts (R7 cells) and P6 cells, a fibroblast cell line engineered to over-express IGF-IR, were kind gifts from Dr Renato Baserga (Kimmel Cancer Center, PA, USA). Cells were maintained in Dulbecco's modified Eagle's medium with high glucose (Gibco/BRL) with 9% fetal bovine serum (Gibco/BRL) supplemented with penicillin/streptomycin antibiotics (Gibco/BRL). The 9% concentration of FBS resulted from addition of 50 ml of filtered serum to 500 ml of DMEM to a total volume of 550 ml. R7 cells were maintained in media containing 34 mg G418/litre (Sigma). Cells were cultured at 378C with 5% carbon dioxide. NIH3T3 cells were obtained from the American Type Culture Collection (ATCC 1658) and were cultured in DMEM high glucose, with 9% calf serum. BOSC 23 murine retroviral packaging cells used to produce ecotropic viruses were a kind gift of Dr Rob Kay (Terry Fox Laboratories, Vancouver, Canada), and were cultured in 9% fetal bovine serum in DMEM.
Retroviral constructs
Infections of R7 and NIH3T3 fibroblasts were carried out using the Murine Stem Cell Virus (MSCV) retroviral expression system (Clontech). Briefly, the BOSC23 packaging cell line was transfected with target plasmids using the calcium phosphate method as previously described (Pear et al., 1993) . The R7EN and NIH3T3 EN cell lines were generated using MSCV puromycin vectors containing the full length ETV6-NTRK3 cDNA (accession #AF041811) as described (Wai et al., 2000) . The R+ cell line was generated by infection of R7 cells using the MSCV hygromycin vector containing full length IGFRI cDNA. A SalI/EcoRI fragment of pGR13 (a gift of Dr Renato Baserga) containing the full length cDNA for IGFRI was ligated into the XhoI/EcoRI sites in the MSCV hygromycin vector. Verification of the identity and orientation of the IGFRI cDNA in each vector was carried out using sequencing and restriction enzyme digest analysis. Cells expressing activated Ha-Ras were made by transfection of pCTV 2.11 containing activated V12 HaRas (a gift of Dr Rob Kay) in conjunction with the BOSC 23 packaging system and puromycin selection as described (Wai et al., 2000) .
Soft agar colony assays
Cells were plated at a density of 2000 cells per milliliter of 0.2% agarose supplemented with 10% FBS over an underlayer of 0.4% agarose/10% FBS in DMEM. Each experiment was carried out in triplicate in 35 mm wells for each cell line. Cell lines were examined in a minimum of seven separate soft agar experiments. Colony formation was assessed at 2 weeks by macroscopic colony formation. All colonies greater than 0.1 mm in size were counted along with all single cells in each high-powered field (406 objective). Ten high powered-fields per well were counted for a total of 30 counts per experiment. The results are represented as the ratio of macroscopic colonies per total cells plated (single cells plus colonies). Statistical analysis was carried out using the Student's t-test. Statistical significance was set at a P-value 50.05.
Northern blotting
Total RNA was extracted from primary frozen tumor samples and cell lines using the acid guanidinium-phenol/ chloroform method as previously described (Sambrook et al., 1989) . Northern blotting was carried out using 20 mg of total RNA and following standard protocols (Sambrook et al., 1989) . A 500 base-pair IGF2 probe was generated by RT -PCR of human RNA using primers specific for IGF2 exon 9, including 5'-CTTGGATTTGAGTCAAATTGG-3' (sense primer) and 5'-CCTCCTTTGGTCTTACTGGG-3' (antisense primer). The PCR cycling parameters were as follows: one 30 s denaturation cycle at 958C, followed by 25 cycles at 958C for 30 s, 588C for 1 min, 728C for 1 min, and followed by a final incubation of 688C for 10 min. The IGF2 PCR product was purified using a Qiagen gel extraction kit. The bactin probe for RNA integrity was obtained from Clontech.
Western blotting and immunoprecipitation
Cells were cultured in either 9% serum or in 0.5% serum for 18 h (to synchronize cells in G 0 ) and then stimulated with 9% serum or differing concentrations of purified IGF1 or IGF2 as indicated in the figure legends. Cells were cultured to *75% confluence, and either starved or stimulated as indicated and then rinsed twice with PBS followed by lysis as previously described (Obermeier et al., 1993) . Cell lysates were cleared by centrifugation and protein concentrations were determined using Biorad protein quantification kit (Dc Protein Assay Kit). Immunoprecipitation was carried out with protein A-conjugated Sepharose beads (Amersham) overnight at 48C with mixing. The beads were washed three times with lysis buffer. Samples for both Western blotting and from immunoprecipitation were mixed with Laemmli buffer and separated by electrophoresis on 10 -15% gels according to standard protocols (Sambrook et al., 1989) . The proteins were transferred to Immobilon-P membrane (Millipore) and blocked in 5% bovine serum albumin. Analysis was carried out with the indicated antibodies and detection was achieved with ECL according to the manufacturer's protocol (Amersham). The antibodies used were as follows: a-IR3 a-IGFRI mouse monoclonal (Calbiochem), a-Grb2 mouse polyclonal (Transduction Laboratories), a-phosphoMek1/2 Ser217/221 rabbit polyclonal (New England Biolabs), a-phospho-Akt Ser473 rabbit polyclonal (New England Biolabs), a-Cyclin D1/2 mouse monoclonal (Upstate Biotechnology), a-IGF-IR b-subunit rabbit polyclonal antibody (Santa Cruz), a-NTRK3 rabbit polyclonal antibody (Santa Cruz), a-C-terminal IRS-1 rabbit polyclonal (Upstate Biotechnology), a-p85 PI-3K (Transduction Laboratories), a-PLCg (Transduction Laboratories), and a-Tel (ETV6) rabbit polyclonal (P Marynen, University of Leiden, Belgium). Purified IGF1 and IGF2 peptides were obtained from Sigma.
Site-directed mutagenesis
Site-directed mutagenesis was carried out using the Stratagene QuikChange Site Directed Mutagenesis Kit. This was used to create the EN kinase dead (EN-K380N) mutant as well as the PLCg-binding mutant using methods as previously described (Wai et al., 2000) . The Y560F and Y594F mutants were created using the same kit with the following primers; 5'-GAGATCTTCACCTTTGGAAAGCAGCC-3' for the Y560F mutant, and the 5'-CCCAAAGAGGTGTTC-GATGTCATGCTG-3' for the Y594F mutant. The DNA sequence of the mutants was verified by sequence analysis. The PCR cycling parameters were as follows: one 30 s denaturation cycle at 958C, followed by 18 cycles at 958C for 30 s, 558C for 1 min, 728C for 10 min, and followed by a final incubation of 688C for 10 min.
